NCT04471974View on ClinicalTrials.gov

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaMetastatic Prostate Small Cell CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

DRUG

Enzalutamide

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

48109

University of Michigan, Ann Arbor

60805

University of Chicago, Evergreen Park

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Zenith Epigenetics
All Listed Sponsors
collaborator

Zenith Epigenetics

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

U.S. Army Medical Research and Development Command

FED

lead

Rahul Aggarwal

OTHER